Evinacumab for plaque buildup in HoFH
Part of Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This observational study looks at how adding evinacumab to standard cholesterol-lowering therapy affects plaque in the heart arteries of people with homozygous familial hypercholesterolemia (HoFH). It compares those who started evinacumab within the last 2 years to those on standard therapy alone, using CT scans taken before and after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years or older (18 in Italy or France).
- You must have a diagnosis of homozygous familial hypercholesterolemia (HoFH), a genetic condition causing very high cholesterol.
- If you are in the evinacumab group: you must have started evinacumab within the past 2 years and have a CT scan before and 18-24 months after starting it.
- If you are in the standard therapy group: you must be on stable cholesterol-lowering medications (like statins, ezetimibe, or PCSK9 inhibitors) and have two CT scans 18-24 months apart.
- Your LDL cholesterol must be 140 mg/dL or higher despite current treatment.
- You can have had bypass surgery on only one heart artery, but not on multiple arteries.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, EDP167, for people with homozygous familial hypercholesterolemia (HoFH), a genetic condition that causes very high cholesterol. The goal is to see if EDP167 can lower 'bad' cholesterol (LDL-C).
This trial tests a new medicine, CTX310, for people with persistently high levels of fats (triglycerides) and cholesterol that have not improved with standard treatments. It aims to see if the drug is safe and tolerable.
This trial follows people with a genetic high-cholesterol condition (HeFH) who had a heart scan at least 5 years ago. Researchers will do a new scan to see how their heart arteries have changed over time, without any experimental treatments.
This study tests whether starting evolocumab (a cholesterol-lowering injection) soon after a heart attack helps prevent future heart problems. You'll receive the study drug or placebo for 52 weeks while your heart is monitored with imaging scans.
This study uses a heart CT scan to look for plaque buildup in the arteries of people with familial hypercholesterolemia (a genetic high-cholesterol condition). It aims to understand why some people with FH develop heart disease while others don't.
This trial studies whether lowering LDL (“bad cholesterol”) with a PCSK-9 inhibitor (evolocumab) improves blood flow to the heart, measured by special PET scans. It’s for people over a certain age who have stable coronary artery disease and a higher risk of heart problems.
Hear when a new Homozygous Familial Hypercholesterolemia (HoFH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.